Niklas Hammar

16.1k total citations · 4 hit papers
262 papers, 11.1k citations indexed

About

Niklas Hammar is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, Niklas Hammar has authored 262 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Endocrinology, Diabetes and Metabolism, 52 papers in Cardiology and Cardiovascular Medicine and 44 papers in Epidemiology. Recurrent topics in Niklas Hammar's work include Diabetes Treatment and Management (36 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (34 papers) and Metabolism, Diabetes, and Cancer (27 papers). Niklas Hammar is often cited by papers focused on Diabetes Treatment and Management (36 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (34 papers) and Metabolism, Diabetes, and Cancer (27 papers). Niklas Hammar collaborates with scholars based in Sweden, United Kingdom and United States. Niklas Hammar's co-authors include Göran Walldius, Ingmar Jungner, Lars Alfredsson, Måns Rosén, Hans Garmo, Leif Friberg, Mieke Van Hemelrijck, Björn Wettermark, Ulf Bergman and Anders Sundström and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Niklas Hammar

255 papers receiving 10.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months

2006 1.5k citations Niklas Hammar et al. profile →
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

2017 604 citations Mikhail Kosiborod, Matthew A. Cavender et al. Circulation profile →
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review

2017 263 citations Kamlesh Khunti, Marília Brito Gomes et al. Diabetes Obesity and Metabolism profile →
Metabolic Profile and Long-Term Risk of Depression, Anxiety, and Stress-Related Disorders

2024 45 citations Dang Wei, Niklas Hammar et al. profile →

Peers

Countries citing papers authored by Niklas Hammar

Since Specialization

Citations

This map shows the geographic impact of Niklas Hammar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niklas Hammar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niklas Hammar more than expected).

Fields of papers citing papers by Niklas Hammar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niklas Hammar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niklas Hammar. The network helps show where Niklas Hammar may publish in the future.

Co-authorship network of co-authors of Niklas Hammar

This figure shows the co-authorship network connecting the top 25 collaborators of Niklas Hammar. A scholar is included among the top collaborators of Niklas Hammar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niklas Hammar. Niklas Hammar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Use of new CORE risk score to predict 10 year risk of liver cirrhosis in general population: population based cohort study 2025 ·BMJ ·(unknown), Fredrik Åberg, (unknown), Panu K. Luukkonen, Veikko Salomaa, Antti Jula, Annamari Lundqvist, Satu Männistö, (unknown), Mats Talbäck, Niklas Hammar, Hannes Hagström	1
2	Dysglycaemia and incident aortic stenosis: a cohort study 2025 ·Heart ·(unknown), Pia Lundman, Leif Friberg, Mats Talbäck, Niklas Hammar, Göran Walldius, Mozhu Ding, Anna Norhammar	2
3	Surgical removal of tonsils and risk of COVID-19: a nested case–control study using data from UK Biobank and AMORIS Cohort 2024 ·BMC Medicine ·Yanping Yang, Kejia Hu, Karin Modig, (unknown), Imre Janszky, Niklas Hammar, Fang Fang, Zhe Zhang, Dang Wei	0
4	Biomarkers for Prediction of Alcohol-Related Liver Cirrhosis: A General Population–Based Swedish Study of 537,250 Individuals 2024 ·Clinical Gastroenterology and Hepatology ·(unknown), Mats Talbäck, Niklas Hammar, Ying Shang, Hannes Hagström	0
5	HbA1c trajectories over 3 years in people with type 2 diabetes starting second‐line glucose‐lowering therapy: The prospective global DISCOVER study 2023 ·Diabetes Obesity and Metabolism ·Brenda Bongaerts, Oliver Kuß, Fabrice Bonnet, Hungta Chen, Andrew Cooper, Peter Fenici, Marília Brito Gomes, Niklas Hammar, Linong Ji, Kamlesh Khunti, Jesús Medina, Antonio Nicolucci, М. В. Шестакова, Hirotaka Watada, Wolfgang Rathmann	2
6	Blood biomarker profiles and exceptional longevity: comparison of centenarians and non-centenarians in a 35-year follow-up of the Swedish AMORIS cohort 2023 ·GeroScience ·Shunsuke Murata, Marcus Ebeling, Anna C. Meyer, (unknown), Niklas Hammar, Karin Modig	14
7	Lipid levels in midlife and risk of atrial fibrillation over 3 decades—Experience from the Swedish AMORIS cohort: A cohort study 2022 ·PLoS Medicine ·Mozhu Ding, Alexandra Wennberg, Bruna Gigante, Göran Walldius, Niklas Hammar, Karin Modig	23
8	Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study 2021 ·PLoS Medicine ·Göran Walldius, Ulf dé Fairé, Lars Alfredsson, Karin Leander, Peter Westerholm, Håkan Malmström, Torbjörn Ivert, Niklas Hammar	38
9	Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study 2021 ·Diabetes Obesity and Metabolism ·Kamlesh Khunti, B Charbonnel, Hungta Chen, David Z.I. Cherney, Andrew Cooper, Peter Fenici, Marília Brito Gomes, Niklas Hammar, Hiddo J.L. Heerspink, Linong Ji, Jesús Medina, Antonio Nicolucci, (unknown), Wolfgang Rathmann, М. В. Шестакова, Iichiro Shimomura, Fengming Tang, Hirotaka Watada, Mikhail Kosiborod, (unknown)	13
10	Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study 2020 ·Diabetes Obesity and Metabolism ·Krishna Patel, Marília Brito Gomes, B Charbonnel, Hungta Chen, Javier Cid‐Ruzafa, Peter Fenici, Niklas Hammar, Linong Ji, Kevin F. Kennedy, Kamlesh Khunti, Mikhail Kosiborod, Stuart Pocock, М. В. Шестакова, Iichiro Shimomura, Filip Surmont, Hirotaka Watada, (unknown)	7
11	Association of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis 2020 ·Cancer Epidemiology Biomarkers & Prevention ·(unknown), Gincy George, Sam Sollie, Debra H. Josephs, Niklas Hammar, Göran Walldius, Sophia N. Karagiannis, Mieke Van Hemelrijck	16
12	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs breakdown → 2017 ·Circulation ·Mikhail Kosiborod, Matthew A. Cavender, Alex Z. Fu, John Wilding, Kamlesh Khunti, Reinhard W. Holl, Anna Norhammar, Kåre I. Birkeland, Marit E. Jørgensen, Marcus Thuresson, Niki Arya, Johan Bodegård, Niklas Hammar, Peter Fenici	604
13	A latent class model for competing risks 2017 ·Statistics in Medicine ·M. Rowley, Hans Garmo, Mieke Van Hemelrijck, Wahyu Wulaningsih, Birgitta Grundmark, Björn Zethelius, Niklas Hammar, (unknown), Masato Inoue, Lars Holmberg, A C C Coolen	10
14	Serum inflammatory markers and colorectal cancer risk and survival 2017 ·British Journal of Cancer ·(unknown), Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, Håkan Malmström, Mats Lambe, Niklas Hammar, Göran Walldius, Ingmar Jungner, Wahyu Wulaningsih	62
15	Biomarker-based score to predict mortality in persons aged 50 years and older: a new approach in the Swedish AMORIS study. 2012 ·Research Portal (King's College London) ·Mieke Van Hemelrijck, Danielle Harari, Hans Garmo, Niklas Hammar, Göran Walldius, Mats Lambe, Ingmar Jungner, Lars Holmberg	29
16	Low mortality and myocardial infarction incidence among flying personnel during working career and beyond 2010 ·Scandinavian Journal of Work Environment & Health ·Anette Linnersjö, Lars‐Åke Brodin, Carin Andersson, Lars Alfredsson, Niklas Hammar	12
17	Lipoprotein Components and Risk of Congestive Heart Failure in 84 740 Men and Women in the Apolipoprotein MOrtality RISk Study (AMORIS) 2009 ·European Journal of Heart Failure ·Ingar Holme, Are H. Aastveit, Niklas Hammar, Ingmar Jungner, Göran Walldius	29
18	Elevated glycosylated haemoglobin (HbA_1c) is a risk marker in coronary artery bypass surgery 2008 ·Scandinavian Cardiovascular Journal ·(unknown), R. E. Anderson, Niklas Hammar, Tobias Nordqvist, Torbjörn Ivert	54
19	Time trends in the incidence of myocardial infarction among professional drivers in Stockholm 1977-96 : Journal of Occupational and Environmental Medicine 2004 ·Journal of Occupational and Environmental Medicine ·Carolina Bigert, (unknown), Niklas Hammar, Johan Hallqvist, Per Gustavsson	6
20	[A certain increase of skin cancer among pilots]. 2003 ·PubMed ·Niklas Hammar, Harald Eliasch, Anette Linnersjö, (unknown), (unknown), Eero Pukkala	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact